MOESM2 of A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum

Additional file 2: Figure S1. Overview of the design of the two clinical vaccine studies from which the serum samples have been derived

Multivariable logistic regression analysis for the effect avidity on clinical malaria.

<p>Multivariable logistic regression analysis for the effect avidity on clinical malaria.</p

Box plot of anti-CS antibody avidity by level of malaria exposure (based on malaria exposure index) at 1, ∼8 and 12 months post dose 3.

<p>Box plot of anti-CS antibody avidity by level of malaria exposure (based on malaria exposure index) at 1, ∼8 and 12 months post dose 3.</p

Avidity indices in cases, controls and a subset of 19 controls with high exposure rates and low anti-CS titers at different sampling times.

<p><i>CI: Confidence Intervals.</i></p><p><i>*p value for the comparison between cases and controls (all).</i></p><p>Avidity indices in cases, controls and a subset of 19 controls with high exposure rates and low anti-CS titers at different sampling times.</p

Panel A: Anti-CS titers in cases, controls and 19 protected children with low anti-CS antibodies titer and high malaria exposure index during 15 months of follow-up.

<p>Panel B: Matrix diagram showing correlation between antibody avidity measured at three time points during the follow up. Significant correlation observed between AI at 1 month post-dose 3 and at ∼8 months post-dose 3 (r = 0.33, p value = 0.0111) and at 1 month and 12 months post-dose 3 (r = 0.48, p value = 0.0002). Panel C: Correlation between anti-CS antibody avidity at 1 month post dose 3 and age (r = 0.003, p value = 0.656) Panel D: Correlation between anti-CS antibody avidity and anti-CS antibody titers at 1 month post dose 3 (r = –0.03; p value = 0.859).</p